clofazimine has been researched along with Tuberculosis in 68 studies
Clofazimine: A fat-soluble riminophenazine dye used for the treatment of leprosy. It has been used investigationally in combination with other antimycobacterial drugs to treat Mycobacterium avium infections in AIDS patients. Clofazimine also has a marked anti-inflammatory effect and is given to control the leprosy reaction, erythema nodosum leprosum. (From AMA Drug Evaluations Annual, 1993, p1619)
clofazimine : 3-Isopropylimino-3,5-dihydro-phenazine in which the hydrogen at position 5 is substituted substituted by a 4-chlorophenyl group, and that at position 2 is substituted by a (4-chlorophenyl)amino group. A dark red crystalline solid, clofazimine is an antimycobacterial and is one of the main drugs used for the treatment of multi-bacillary leprosy. However, it can cause red/brown discolouration of the skin, so other treatments are often preferred in light-skinned patients.
Tuberculosis: Any of the infectious diseases of man and other animals caused by species of MYCOBACTERIUM TUBERCULOSIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Clofazimine is classified as a WHO group B drug for the treatment of rifampin-resistant tuberculosis." | 9.41 | Effect of Clofazimine Concentration on QT Prolongation in Patients Treated for Tuberculosis. ( Abdelwahab, MT; Court, R; Dawson, R; Denti, P; Diacon, AH; Everitt, D; Maartens, G; Svensson, EM, 2021) |
| "Pyrazinamide (PZA) has remained a keystone of tuberculosis (TB) therapy, and it possesses high imperative sterilizing action that can facilitate reduction in the present chemotherapy regimen." | 9.22 | Mutations Associated with Pyrazinamide Resistance in Mycobacterium tuberculosis: A Review and Update. ( Palaniyandi, K; Rajendran, A, 2022) |
| "Bedaquiline (BDQ) is a potent drug for treating drug-resistant tuberculosis (TB)." | 8.31 | Bedaquiline resistance pattern in clofazimine-resistant clinical isolates of tuberculosis patients. ( Chen, S; Chu, N; Dong, L; Huang, H; Huo, F; Jiang, G; Jing, W; Nie, W; Shang, Y; Shi, W; Xue, Y, 2023) |
| "Clofazimine (CFZ) is an important component of the World Health Organization's (WHO) recommended all-oral drug regimen for treatment of multi-drug resistant tuberculosis (MDR-TB)." | 8.31 | Development of low-cost, weight-adjustable clofazimine mini-tablets for treatment of tuberculosis in pediatrics. ( Brunaugh, A; Koleng, JJ; Martins, PP; Parekh, J; Smyth, HDC; Trementozzi, A; Warnken, Z, 2023) |
| "The chemotherapeutic regimens of patients with drug-susceptible (DS)- tuberculosis (TB) comprise four primary anti-TB drugs: rifampicin (RMP), isoniazid (INH), ethambutol (EMB) and pyrazinamide (PZA), administered for six-to-nine months." | 8.12 | Assessment of the efficacy of clofazimine alone and in combination with primary agents against Mycobacterium tuberculosis in vitro. ( Anderson, R; Cholo, MC; Mashele, SA; Matjokotja, MT; Rasehlo, SSM; Steel, HC, 2022) |
| "TBI-166, derived from riminophenazine analogues, shows more potent anti-TB activity than clofazimine and is being assessed against tuberculosis (TB) in a phase IIa clinical trial in China." | 8.12 | Superior Efficacy of a TBI-166, Bedaquiline, and Pyrazinamide Combination Regimen in a Murine Model of Tuberculosis. ( Chen, X; Ding, Y; Fu, L; Guo, S; Liu, H; Lu, Y; Wang, B; Wang, N; Zhang, W; Zhu, H, 2022) |
| "Clofazimine and high-dose rifapentine have each separately been associated with treatment-shortening activity when incorporated into tuberculosis (TB) treatment regimens." | 7.91 | Treatment-Shortening Effect of a Novel Regimen Combining Clofazimine and High-Dose Rifapentine in Pathologically Distinct Mouse Models of Tuberculosis. ( Ammerman, NC; Chaisson, RE; Chang, YS; Grosset, JH; Jain, S; Nuermberger, E; Saini, V; Tasneen, R, 2019) |
| "The antileprosy drug clofazimine was recently repurposed as part of a newly endorsed short-course regimen for multidrug-resistant tuberculosis." | 7.88 | Impact of Clofazimine Dosing on Treatment Shortening of the First-Line Regimen in a Mouse Model of Tuberculosis. ( Almeida, DV; Ammerman, NC; Bautista, EM; Bester, LA; Betoudji, F; Chaisson, RE; Chang, YS; Grosset, JH; Guo, H; Li, SY; Moodley, C; Ngcobo, B; Nuermberger, E; Omansen, TF; Pillay, L; Saini, V; Singh, SD; Swanson, RV; Tapley, A; Tasneen, R; Tyagi, S, 2018) |
| "First extensive reformulation of clofazimine (CLZ) in nanoporous silica particles (NSPs) for tackling antibiotic-resistant tuberculosis (TB) infections." | 7.85 | Clofazimine encapsulation in nanoporous silica particles for the oral treatment of antibiotic-resistant Mycobacterium tuberculosis infections. ( Andersson, M; Bernet-Camard, MF; Brodin, P; Costa-Gouveia, J; Feiler, A; Valetti, S; Xia, X, 2017) |
| "Experimental and clinical studies have indicated that the antileprosy drug clofazimine may contribute treatment-shortening activity when included in tuberculosis treatment regimens." | 7.83 | Clofazimine Contributes Sustained Antimicrobial Activity after Treatment Cessation in a Mouse Model of Tuberculosis Chemotherapy. ( Adamson, J; Almeida, DV; Ammerman, NC; Bester, LA; Dorasamy, A; Grosset, JH; Mgaga, Z; Moodley, C; Moodley, S; Ngcobo, B; Singh, SD; Swanson, RV, 2016) |
| "A key drug for the treatment of leprosy, clofazimine has recently been associated with highly effective and significantly shortened regimens for the treatment of multidrug-resistant tuberculosis (TB)." | 7.81 | Clofazimine shortens the duration of the first-line treatment regimen for experimental chemotherapy of tuberculosis. ( Adamson, J; Almeida, DV; Ammerman, NC; Converse, PJ; Grosset, JH; Li, SY; Swanson, RV; Tyagi, S, 2015) |
| "The antileprosy drug clofazimine has shown potential for shortening tuberculosis treatment; however, the current dosing of the drug is not evidence based, and the optimal dosing is unknown." | 7.81 | Pharmacokinetics and pharmacodynamics of clofazimine in a mouse model of tuberculosis. ( Adamson, J; Almeida, DV; Ammerman, NC; Bester, LA; Dorasamy, A; Grosset, JH; Mgaga, Z; Moodley, C; Moodley, S; Ngcobo, B; Singh, S; Swanson, RV; Tapley, A, 2015) |
| "Bedaquiline (BDQ), an ATP synthase inhibitor, is the first drug to be approved for treatment of multi-drug resistant tuberculosis in decades." | 7.80 | Acquired resistance of Mycobacterium tuberculosis to bedaquiline. ( Andries, K; Coeck, N; de Jong, BC; Gevers, T; Koul, A; Lounis, N; Thys, K; Villellas, C; Vranckx, L, 2014) |
| "Inhalable clofazimine-containing dry powder microparticles (CFM-DPI) and native clofazimine (CFM) were evaluated for activity against Mycobacterium tuberculosis in human monocyte-derived macrophage cultures and in mice infected with a low-dose aerosol." | 7.79 | Inhaled microparticles containing clofazimine are efficacious in treatment of experimental tuberculosis in mice. ( Agrawal, AK; Anderson, R; Cholo, M; Fourie, PB; Germishuizen, WA; Gupta, P; Gupta, UD; Misra, A; Mohan, M; Motheo, MP; Singh, AK; Verma, RK, 2013) |
| "The therapeutic efficacy of liposomal clofazimine (L-CLF) was studied in mice infected with Mycobacterium tuberculosis Erdman." | 7.70 | Effective treatment of acute and chronic murine tuberculosis with liposome-encapsulated clofazimine. ( Adams, LB; Franzblau, SG; Krahenbuhl, JL; Mehta, RT; Sinha, I, 1999) |
| "In our efforts to develop new drugs for the treatment of tuberculosis, especially that caused by multidrug-resistant strains, we investigated clofazimine (CFM) and two of its analogs, B4154 and B4157, for their antituberculosis activities." | 7.69 | Antituberculosis activities of clofazimine and its new analogs B4154 and B4157. ( Daneluzzi, D; Gangadharam, PR; Nadadhur, G; O'Sullivan, JF; Reddy, VM, 1996) |
| " However, clinical implications may be restricted owing to poor solubility and low bioavailability rendering a suboptimal drug concentration in the target organ." | 5.91 | Clofazimine nanoclusters show high efficacy in experimental TB with amelioration in paradoxical lung inflammation. ( Jadhav, K; Jhilta, A; Ray, E; Sharma, N; Shukla, R; Singh, AK; Singh, R; Verma, RK, 2023) |
| " Increased lung and spleen accumulation of the drug after pulmonary administration was noted in infected mice compared to naive mice, while the opposite trend was noted in the oral dosing groups." | 5.72 | Respirable Clofazimine Particles Produced by Air Jet Milling Technique Are Efficacious in Treatment of BALB/c Mice with Chronic Mycobacterium tuberculosis Infection. ( Brunaugh, AD; Gonzalez-Juarrero, M; Koleng, JJ; Munoz Gutierrez, J; Pearce, C; Smyth, HDC; Walz, A; Warnken, Z, 2022) |
| "Clofazimine is classified as a WHO group B drug for the treatment of rifampin-resistant tuberculosis." | 5.41 | Effect of Clofazimine Concentration on QT Prolongation in Patients Treated for Tuberculosis. ( Abdelwahab, MT; Court, R; Dawson, R; Denti, P; Diacon, AH; Everitt, D; Maartens, G; Svensson, EM, 2021) |
| " Eleven of these more water-soluble riminophenazine analogs possess shorter half-lives than clofazimine when dosed orally to mice, suggesting that they may accumulate less." | 5.37 | Clofazimine analogs with efficacy against experimental tuberculosis and reduced potential for accumulation. ( Fu, L; Huang, H; Jin, H; Li, P; Lu, Y; Ma, Z; Upton, AM; Wang, B; Xu, J; Yin, D; Zhao, W; Zheng, M; Zhu, H, 2011) |
| "Clofazimine has in vitro and in vivo activities against M." | 5.35 | [Activities of clofazimine against Mycobacterium tuberculosis in vitro and in vivo]. ( Chu, NH; Li, P; Liang, BW; Lu, Y; Wang, B; Zhao, WJ; Zheng, MQ, 2008) |
| "Pyrazinamide (PZA) has remained a keystone of tuberculosis (TB) therapy, and it possesses high imperative sterilizing action that can facilitate reduction in the present chemotherapy regimen." | 5.22 | Mutations Associated with Pyrazinamide Resistance in Mycobacterium tuberculosis: A Review and Update. ( Palaniyandi, K; Rajendran, A, 2022) |
| "Clofazimine (CFZ) is an important component of the World Health Organization's (WHO) recommended all-oral drug regimen for treatment of multi-drug resistant tuberculosis (MDR-TB)." | 4.31 | Development of low-cost, weight-adjustable clofazimine mini-tablets for treatment of tuberculosis in pediatrics. ( Brunaugh, A; Koleng, JJ; Martins, PP; Parekh, J; Smyth, HDC; Trementozzi, A; Warnken, Z, 2023) |
| "BACKGROUND: Clofazimine (CFZ) is routinely used worldwide for the treatment of leprosy and TB." | 4.31 | Extemporaneously compounded liquid formulations of clofazimine. ( Fourie, CL; Garcia-Prats, AJ; Hesseling, AC; Hoddinott, G; Jew, RK; Nahata, MC; Pande, PG; Scarim, A; Scarim, J; Schaaf, HS; Taneja, R, 2023) |
| "Bedaquiline (BDQ) is a potent drug for treating drug-resistant tuberculosis (TB)." | 4.31 | Bedaquiline resistance pattern in clofazimine-resistant clinical isolates of tuberculosis patients. ( Chen, S; Chu, N; Dong, L; Huang, H; Huo, F; Jiang, G; Jing, W; Nie, W; Shang, Y; Shi, W; Xue, Y, 2023) |
| "The chemotherapeutic regimens of patients with drug-susceptible (DS)- tuberculosis (TB) comprise four primary anti-TB drugs: rifampicin (RMP), isoniazid (INH), ethambutol (EMB) and pyrazinamide (PZA), administered for six-to-nine months." | 4.12 | Assessment of the efficacy of clofazimine alone and in combination with primary agents against Mycobacterium tuberculosis in vitro. ( Anderson, R; Cholo, MC; Mashele, SA; Matjokotja, MT; Rasehlo, SSM; Steel, HC, 2022) |
| "TBI-166, derived from riminophenazine analogues, shows more potent anti-TB activity than clofazimine and is being assessed against tuberculosis (TB) in a phase IIa clinical trial in China." | 4.12 | Superior Efficacy of a TBI-166, Bedaquiline, and Pyrazinamide Combination Regimen in a Murine Model of Tuberculosis. ( Chen, X; Ding, Y; Fu, L; Guo, S; Liu, H; Lu, Y; Wang, B; Wang, N; Zhang, W; Zhu, H, 2022) |
| "Clofazimine and high-dose rifapentine have each separately been associated with treatment-shortening activity when incorporated into tuberculosis (TB) treatment regimens." | 3.91 | Treatment-Shortening Effect of a Novel Regimen Combining Clofazimine and High-Dose Rifapentine in Pathologically Distinct Mouse Models of Tuberculosis. ( Ammerman, NC; Chaisson, RE; Chang, YS; Grosset, JH; Jain, S; Nuermberger, E; Saini, V; Tasneen, R, 2019) |
| "The antileprosy drug clofazimine was recently repurposed as part of a newly endorsed short-course regimen for multidrug-resistant tuberculosis." | 3.88 | Impact of Clofazimine Dosing on Treatment Shortening of the First-Line Regimen in a Mouse Model of Tuberculosis. ( Almeida, DV; Ammerman, NC; Bautista, EM; Bester, LA; Betoudji, F; Chaisson, RE; Chang, YS; Grosset, JH; Guo, H; Li, SY; Moodley, C; Ngcobo, B; Nuermberger, E; Omansen, TF; Pillay, L; Saini, V; Singh, SD; Swanson, RV; Tapley, A; Tasneen, R; Tyagi, S, 2018) |
| "First extensive reformulation of clofazimine (CLZ) in nanoporous silica particles (NSPs) for tackling antibiotic-resistant tuberculosis (TB) infections." | 3.85 | Clofazimine encapsulation in nanoporous silica particles for the oral treatment of antibiotic-resistant Mycobacterium tuberculosis infections. ( Andersson, M; Bernet-Camard, MF; Brodin, P; Costa-Gouveia, J; Feiler, A; Valetti, S; Xia, X, 2017) |
| "Clofazimine (CFZ) is highly active against mycobacterium, including resistant Mycobacterium tuberculosis, but its therapeutic efficacy via the oral route is limited by severe adverse effects, poor aqueous solubility, and slow onset of action." | 3.85 | Excipient-Free Pulmonary Delivery and Macrophage Targeting of Clofazimine via Air Jet Micronization. ( Brunaugh, AD; Ferrati, S; Jan, SU; Smyth, HDC, 2017) |
| "Experimental and clinical studies have indicated that the antileprosy drug clofazimine may contribute treatment-shortening activity when included in tuberculosis treatment regimens." | 3.83 | Clofazimine Contributes Sustained Antimicrobial Activity after Treatment Cessation in a Mouse Model of Tuberculosis Chemotherapy. ( Adamson, J; Almeida, DV; Ammerman, NC; Bester, LA; Dorasamy, A; Grosset, JH; Mgaga, Z; Moodley, C; Moodley, S; Ngcobo, B; Singh, SD; Swanson, RV, 2016) |
| "The antileprosy drug clofazimine has shown potential for shortening tuberculosis treatment; however, the current dosing of the drug is not evidence based, and the optimal dosing is unknown." | 3.81 | Pharmacokinetics and pharmacodynamics of clofazimine in a mouse model of tuberculosis. ( Adamson, J; Almeida, DV; Ammerman, NC; Bester, LA; Dorasamy, A; Grosset, JH; Mgaga, Z; Moodley, C; Moodley, S; Ngcobo, B; Singh, S; Swanson, RV; Tapley, A, 2015) |
| "A key drug for the treatment of leprosy, clofazimine has recently been associated with highly effective and significantly shortened regimens for the treatment of multidrug-resistant tuberculosis (TB)." | 3.81 | Clofazimine shortens the duration of the first-line treatment regimen for experimental chemotherapy of tuberculosis. ( Adamson, J; Almeida, DV; Ammerman, NC; Converse, PJ; Grosset, JH; Li, SY; Swanson, RV; Tyagi, S, 2015) |
| "Clofazimine, a member of the riminophenazine class, is one of the few antibiotics that are still active against multidrug-resistant Mycobacterium tuberculosis (M." | 3.80 | Synthesis and biological evaluation of novel 2-methoxypyridylamino-substituted riminophenazine derivatives as antituberculosis agents. ( Cooper, CB; Fu, L; Huang, H; Liu, Y; Lu, Y; Ma, Z; Wang, B; Xu, J; Yin, D; Zhang, C; Zhang, D; Zhang, H, 2014) |
| "Bedaquiline (BDQ), an ATP synthase inhibitor, is the first drug to be approved for treatment of multi-drug resistant tuberculosis in decades." | 3.80 | Acquired resistance of Mycobacterium tuberculosis to bedaquiline. ( Andries, K; Coeck, N; de Jong, BC; Gevers, T; Koul, A; Lounis, N; Thys, K; Villellas, C; Vranckx, L, 2014) |
| "Inhalable clofazimine-containing dry powder microparticles (CFM-DPI) and native clofazimine (CFM) were evaluated for activity against Mycobacterium tuberculosis in human monocyte-derived macrophage cultures and in mice infected with a low-dose aerosol." | 3.79 | Inhaled microparticles containing clofazimine are efficacious in treatment of experimental tuberculosis in mice. ( Agrawal, AK; Anderson, R; Cholo, M; Fourie, PB; Germishuizen, WA; Gupta, P; Gupta, UD; Misra, A; Mohan, M; Motheo, MP; Singh, AK; Verma, RK, 2013) |
| "The therapeutic efficacy of liposomal clofazimine (L-CLF) was studied in mice infected with Mycobacterium tuberculosis Erdman." | 3.70 | Effective treatment of acute and chronic murine tuberculosis with liposome-encapsulated clofazimine. ( Adams, LB; Franzblau, SG; Krahenbuhl, JL; Mehta, RT; Sinha, I, 1999) |
| "In our efforts to develop new drugs for the treatment of tuberculosis, especially that caused by multidrug-resistant strains, we investigated clofazimine (CFM) and two of its analogs, B4154 and B4157, for their antituberculosis activities." | 3.69 | Antituberculosis activities of clofazimine and its new analogs B4154 and B4157. ( Daneluzzi, D; Gangadharam, PR; Nadadhur, G; O'Sullivan, JF; Reddy, VM, 1996) |
| "Patients with the acquired immune deficiency syndrome (AIDS) with disseminated Mycobacterium avium infection have responded poorly to treatment with rifabutine (Ansamycin) and clofazimine, in spite of the good in vitro response of M." | 3.67 | Therapeutic implications of inhibition versus killing of Mycobacterium avium complex by antimicrobial agents. ( Hadley, WK; Nassos, PS; Yajko, DM, 1987) |
| "Tuberculosis is a bacterial disease that predominantly affects the lungs and results in extensive tissue pathology." | 2.49 | A medicinal chemists' guide to the unique difficulties of lead optimization for tuberculosis. ( Barry, CE; Dartois, V, 2013) |
| " However, clinical implications may be restricted owing to poor solubility and low bioavailability rendering a suboptimal drug concentration in the target organ." | 1.91 | Clofazimine nanoclusters show high efficacy in experimental TB with amelioration in paradoxical lung inflammation. ( Jadhav, K; Jhilta, A; Ray, E; Sharma, N; Shukla, R; Singh, AK; Singh, R; Verma, RK, 2023) |
| " Increased lung and spleen accumulation of the drug after pulmonary administration was noted in infected mice compared to naive mice, while the opposite trend was noted in the oral dosing groups." | 1.72 | Respirable Clofazimine Particles Produced by Air Jet Milling Technique Are Efficacious in Treatment of BALB/c Mice with Chronic Mycobacterium tuberculosis Infection. ( Brunaugh, AD; Gonzalez-Juarrero, M; Koleng, JJ; Munoz Gutierrez, J; Pearce, C; Smyth, HDC; Walz, A; Warnken, Z, 2022) |
| "As current treatment of tuberculosis is burdensomely long, provoking non-adherence and drug resistance, effective short-course treatments are needed." | 1.48 | Ultra-rapid near universal TB drug regimen identified via parabolic response surface platform cures mice of both conventional and high susceptibility. ( Clemens, DL; Dillon, BJ; Ho, CM; Horwitz, MA; Lee, BY; Masleša-Galić, S; Nava, S; Silva, A, 2018) |
| "During Mycobacterium tuberculosis infection, a population of bacteria likely becomes refractory to antibiotic killing in the absence of genotypic resistance, making treatment challenging." | 1.38 | Eradication of bacterial persisters with antibiotic-generated hydroxyl radicals. ( Chand, NS; Grant, SS; Haseley, N; Hung, DT; Kaufmann, BB, 2012) |
| " Eleven of these more water-soluble riminophenazine analogs possess shorter half-lives than clofazimine when dosed orally to mice, suggesting that they may accumulate less." | 1.37 | Clofazimine analogs with efficacy against experimental tuberculosis and reduced potential for accumulation. ( Fu, L; Huang, H; Jin, H; Li, P; Lu, Y; Ma, Z; Upton, AM; Wang, B; Xu, J; Yin, D; Zhao, W; Zheng, M; Zhu, H, 2011) |
| "Clofazimine has in vitro and in vivo activities against M." | 1.35 | [Activities of clofazimine against Mycobacterium tuberculosis in vitro and in vivo]. ( Chu, NH; Li, P; Liang, BW; Lu, Y; Wang, B; Zhao, WJ; Zheng, MQ, 2008) |
| " A dose-response experiment was performed with clarithromycin at 50, 100, 200, or 300 mg/kg of body weight administered daily by gavage to mice infected with approximately 10(7) viable MAC." | 1.28 | Activity of clarithromycin against Mycobacterium avium complex infection in beige mice. ( Cynamon, MH; DeStefano, MS; Klemens, SP, 1992) |
| "The activity of TLC G-65 (a liposomal gentamicin preparation), alone and in combination with rifapentine, clarithromycin, clofazimine and ethambutol, was evaluated in the beige mouse (C57BL/6J--bgj/bgj) model of disseminated Mycobacterium avium infection." | 1.28 | TLC G-65 in combination with other agents in the therapy of Mycobacterium avium infection in beige mice. ( Cynamon, MH; Klemens, SP; Swenson, CE, 1992) |
| "Therapeutic efficacy of kanamycin (KM) and clofazimine (CFZ) combined with N2-[(N-acetyl-muramyl)-L-alanyl-D-isoglutaminyl]-N6-stearoyl-L-ly sine, MDP-Lys (L18), against Mycobacterium intracellulare infection induced in mice was studied, based on suppression of incidence of gross lung lesions and bacterial growth at the sites of infection (lungs and spleen), and the following results were obtained." | 1.28 | [Therapeutic efficacy of kanamycin and clofazimine combined with muramyl dipeptide against Mycobacterium intracellulare infection induced in mice]. ( Saito, H; Sato, K; Tomioka, H, 1991) |
| "The in vivo activity of amikacin, used alone or in combination with rifabutin or clofazimine or both, was assessed in the treatment of early and established Mycobacterium avium complex infections in beige mice." | 1.27 | In vivo activity of amikacin alone or in combination with clofazimine or rifabutin or both against acute experimental Mycobacterium avium complex infections in beige mice. ( Gangadharam, PR; Iseman, MD; Kesavalu, L; Perumal, VK; Podapati, NR, 1988) |
| " If chemotherapy is initiated 3 wk after challenge (established infections), the activity of this double drug combination is less effective." | 1.27 | Activity of rifabutin alone or in combination with clofazimine or ethambutol or both against acute and chronic experimental Mycobacterium intracellulare infections. ( Farhi, DC; Gangadharam, PR; Iseman, MD; Jairam, BT; Nguyen, AK; Perumal, VK; Rao, PN, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (5.88) | 18.7374 |
| 1990's | 9 (13.24) | 18.2507 |
| 2000's | 4 (5.88) | 29.6817 |
| 2010's | 31 (45.59) | 24.3611 |
| 2020's | 20 (29.41) | 2.80 |
| Authors | Studies |
|---|---|
| Dartois, V | 1 |
| Barry, CE | 1 |
| Poce, G | 1 |
| Cocozza, M | 1 |
| Consalvi, S | 1 |
| Biava, M | 1 |
| Tonelli, M | 1 |
| Novelli, F | 1 |
| Tasso, B | 1 |
| Sparatore, A | 1 |
| Boido, V | 1 |
| Sparatore, F | 1 |
| Cannas, S | 1 |
| Molicotti, P | 1 |
| Zanetti, S | 1 |
| Parapini, S | 1 |
| Loddo, R | 1 |
| Makarov, V | 1 |
| Salina, E | 1 |
| Reynolds, RC | 1 |
| Kyaw Zin, PP | 1 |
| Ekins, S | 1 |
| Fernandes, GFS | 1 |
| Thompson, AM | 1 |
| Castagnolo, D | 1 |
| Denny, WA | 1 |
| Dos Santos, JL | 1 |
| Cahill, C | 1 |
| Cox, DJ | 1 |
| O'Connell, F | 1 |
| Basdeo, SA | 1 |
| Gogan, KM | 1 |
| Ó'Maoldomhnaigh, C | 1 |
| O'Sullivan, J | 1 |
| Keane, J | 1 |
| Phelan, JJ | 1 |
| Mashele, SA | 1 |
| Steel, HC | 2 |
| Matjokotja, MT | 1 |
| Rasehlo, SSM | 1 |
| Anderson, R | 3 |
| Cholo, MC | 2 |
| Kokesch-Himmelreich, J | 1 |
| Treu, A | 1 |
| Race, AM | 1 |
| Walter, K | 1 |
| Hölscher, C | 1 |
| Römpp, A | 1 |
| Ding, Y | 1 |
| Zhu, H | 2 |
| Fu, L | 3 |
| Zhang, W | 2 |
| Wang, B | 4 |
| Guo, S | 1 |
| Chen, X | 1 |
| Wang, N | 1 |
| Liu, H | 1 |
| Lu, Y | 6 |
| Brunaugh, AD | 2 |
| Walz, A | 1 |
| Warnken, Z | 2 |
| Pearce, C | 1 |
| Munoz Gutierrez, J | 1 |
| Koleng, JJ | 2 |
| Smyth, HDC | 3 |
| Gonzalez-Juarrero, M | 1 |
| Rajendran, A | 1 |
| Palaniyandi, K | 1 |
| Garcia-Prats, AJ | 2 |
| Starke, JR | 1 |
| Waning, B | 1 |
| Kaiser, B | 1 |
| Seddon, JA | 1 |
| Taneja, R | 1 |
| Nahata, MC | 1 |
| Scarim, J | 1 |
| Pande, PG | 1 |
| Scarim, A | 1 |
| Hoddinott, G | 1 |
| Fourie, CL | 1 |
| Jew, RK | 1 |
| Schaaf, HS | 1 |
| Hesseling, AC | 1 |
| Zheng, X | 1 |
| Gui, X | 1 |
| Yao, L | 1 |
| Ma, J | 1 |
| He, Y | 1 |
| Lou, H | 1 |
| Gu, J | 1 |
| Ying, R | 1 |
| Chen, L | 1 |
| Sun, Q | 1 |
| Liu, Y | 2 |
| Ho, CM | 2 |
| Lee, BY | 2 |
| Clemens, DL | 2 |
| Horwitz, MA | 2 |
| Ding, X | 1 |
| Hao, X | 1 |
| Yang, H | 1 |
| Sha, W | 1 |
| Shang, Y | 1 |
| Chen, S | 1 |
| Shi, W | 2 |
| Nie, W | 1 |
| Jing, W | 1 |
| Huo, F | 1 |
| Xue, Y | 1 |
| Dong, L | 1 |
| Jiang, G | 1 |
| Huang, H | 3 |
| Chu, N | 1 |
| Trementozzi, A | 1 |
| Martins, PP | 1 |
| Parekh, J | 1 |
| Brunaugh, A | 1 |
| Jadhav, K | 1 |
| Jhilta, A | 1 |
| Singh, R | 1 |
| Ray, E | 1 |
| Sharma, N | 1 |
| Shukla, R | 1 |
| Singh, AK | 2 |
| Verma, RK | 2 |
| Tanner, L | 1 |
| Evans, JC | 1 |
| Seldon, R | 1 |
| Jordaan, A | 1 |
| Warner, DF | 1 |
| Haynes, RK | 1 |
| Parkinson, CJ | 1 |
| Wiesner, L | 1 |
| Batalha, IL | 1 |
| Bernut, A | 1 |
| Schiebler, M | 1 |
| Ouberai, MM | 1 |
| Passemar, C | 1 |
| Klapholz, C | 1 |
| Kinna, S | 1 |
| Michel, S | 1 |
| Sader, K | 1 |
| Castro-Hartmann, P | 1 |
| Renshaw, SA | 1 |
| Welland, ME | 1 |
| Floto, RA | 1 |
| Ahmad, S | 1 |
| Bhattacharya, D | 1 |
| Gupta, N | 1 |
| Rawat, V | 1 |
| Tousif, S | 1 |
| Van Kaer, L | 1 |
| Das, G | 1 |
| Chaudhary, S | 1 |
| Maji, S | 1 |
| Garg, V | 1 |
| Singh, V | 1 |
| Abdelwahab, MT | 1 |
| Court, R | 1 |
| Everitt, D | 2 |
| Diacon, AH | 2 |
| Dawson, R | 2 |
| Svensson, EM | 1 |
| Maartens, G | 1 |
| Denti, P | 1 |
| de Castro, RR | 1 |
| do Carmo, FA | 1 |
| Martins, C | 1 |
| Simon, A | 1 |
| de Sousa, VP | 1 |
| Rodrigues, CR | 1 |
| Cabral, LM | 1 |
| Sarmento, B | 1 |
| Yu, W | 1 |
| Yusuf, B | 1 |
| Wang, S | 1 |
| Tian, X | 1 |
| Hameed, HMA | 1 |
| Lu, Z | 1 |
| Chiwala, G | 1 |
| Alam, MS | 1 |
| Cook, GM | 1 |
| Maslov, DA | 1 |
| Zhong, N | 1 |
| Zhang, T | 1 |
| Antoine, R | 1 |
| Gaudin, C | 1 |
| Hartkoorn, RC | 1 |
| Valetti, S | 1 |
| Xia, X | 1 |
| Costa-Gouveia, J | 1 |
| Brodin, P | 1 |
| Bernet-Camard, MF | 1 |
| Andersson, M | 1 |
| Feiler, A | 1 |
| Zhang, S | 1 |
| Feng, J | 1 |
| Zhang, Y | 2 |
| Baijnath, S | 1 |
| Moodley, C | 4 |
| Ngcobo, B | 4 |
| Singh, SD | 3 |
| Kruger, HG | 1 |
| Arvidsson, PI | 1 |
| Naicker, T | 1 |
| Pym, A | 1 |
| Govender, T | 1 |
| Xu, J | 3 |
| Tasneen, R | 4 |
| Peloquin, CA | 1 |
| Almeida, DV | 5 |
| Li, SY | 3 |
| Barnes-Boyle, K | 1 |
| Nuermberger, E | 3 |
| Jan, SU | 1 |
| Ferrati, S | 1 |
| Ammerman, NC | 5 |
| Swanson, RV | 4 |
| Bautista, EM | 1 |
| Saini, V | 2 |
| Omansen, TF | 1 |
| Guo, H | 1 |
| Chang, YS | 2 |
| Tapley, A | 2 |
| Tyagi, S | 2 |
| Betoudji, F | 1 |
| Pillay, L | 1 |
| Bester, LA | 3 |
| Chaisson, RE | 2 |
| Grosset, JH | 5 |
| Sng, LH | 1 |
| Peh, JWL | 1 |
| Kee, MTL | 1 |
| Ya'akob, NBM | 1 |
| Ong, RT | 1 |
| Wong, CW | 1 |
| Chee, CBE | 1 |
| Wang, YT | 1 |
| Rancoita, PMV | 1 |
| Cugnata, F | 1 |
| Gibertoni Cruz, AL | 1 |
| Borroni, E | 2 |
| Hoosdally, SJ | 1 |
| Walker, TM | 1 |
| Grazian, C | 1 |
| Davies, TJ | 1 |
| Peto, TEA | 1 |
| Crook, DW | 1 |
| Fowler, PW | 1 |
| Cirillo, DM | 2 |
| Silva, A | 1 |
| Dillon, BJ | 1 |
| Masleša-Galić, S | 1 |
| Nava, S | 1 |
| Jain, S | 1 |
| Ghodousi, A | 1 |
| Rizvi, AH | 1 |
| Baloch, AQ | 1 |
| Ghafoor, A | 1 |
| Khanzada, FM | 1 |
| Qadir, M | 1 |
| Trovato, A | 1 |
| Tahseen, S | 1 |
| Zhang, D | 1 |
| Zhang, C | 1 |
| Zhang, H | 1 |
| Yin, D | 2 |
| Cooper, CB | 1 |
| Ma, Z | 2 |
| Irwin, SM | 1 |
| Gruppo, V | 1 |
| Brooks, E | 1 |
| Gilliland, J | 1 |
| Scherman, M | 1 |
| Reichlen, MJ | 1 |
| Leistikow, R | 1 |
| Kramnik, I | 1 |
| Nuermberger, EL | 2 |
| Voskuil, MI | 1 |
| Lenaerts, AJ | 1 |
| Andries, K | 1 |
| Villellas, C | 1 |
| Coeck, N | 1 |
| Thys, K | 1 |
| Gevers, T | 1 |
| Vranckx, L | 1 |
| Lounis, N | 1 |
| de Jong, BC | 1 |
| Koul, A | 1 |
| Williams, K | 1 |
| Amoabeng, O | 1 |
| Minkowski, A | 1 |
| Mdluli, KE | 1 |
| Upton, AM | 2 |
| Adamson, J | 3 |
| Converse, PJ | 1 |
| von Groote-Bidlingmaier, F | 1 |
| Symons, G | 1 |
| Venter, A | 1 |
| Donald, PR | 1 |
| van Niekerk, C | 1 |
| Hutchings, J | 1 |
| Burger, DA | 1 |
| Schall, R | 1 |
| Mendel, CM | 1 |
| Dorasamy, A | 2 |
| Moodley, S | 2 |
| Mgaga, Z | 2 |
| Singh, S | 1 |
| Grosset, J | 1 |
| Vernon, A | 1 |
| López-Gavín, A | 1 |
| Tudó, G | 1 |
| Vergara, A | 1 |
| Hurtado, JC | 1 |
| Gonzalez-Martín, J | 1 |
| Zheng, MQ | 1 |
| Zhao, WJ | 1 |
| Li, P | 2 |
| Chu, NH | 1 |
| Liang, BW | 1 |
| Zheng, M | 1 |
| Zhao, W | 1 |
| Jin, H | 1 |
| Fourie, PB | 2 |
| Germishuizen, WA | 2 |
| Grant, SS | 1 |
| Kaufmann, BB | 1 |
| Chand, NS | 1 |
| Haseley, N | 1 |
| Hung, DT | 1 |
| Motheo, MP | 1 |
| Agrawal, AK | 1 |
| Mohan, M | 1 |
| Gupta, P | 1 |
| Gupta, UD | 1 |
| Cholo, M | 1 |
| Misra, A | 1 |
| NOUFFLARD, H | 1 |
| BERTEAUX, S | 1 |
| Biswas, SK | 1 |
| Sieber-Ruckstuhl, NS | 1 |
| Sessions, JK | 1 |
| Sanchez, S | 1 |
| Latimer, KS | 1 |
| Greene, CE | 2 |
| Gangadharam, PR | 5 |
| Reddy, MV | 2 |
| Kaufman, AC | 1 |
| Rakich, PM | 1 |
| Weigner, DD | 1 |
| Jagannath, C | 1 |
| Kailasam, S | 1 |
| O'Sullivan, JF | 2 |
| Reddy, VM | 1 |
| Nadadhur, G | 1 |
| Daneluzzi, D | 1 |
| Adams, LB | 1 |
| Sinha, I | 1 |
| Franzblau, SG | 1 |
| Krahenbuhl, JL | 1 |
| Mehta, RT | 1 |
| Klemens, SP | 2 |
| DeStefano, MS | 1 |
| Cynamon, MH | 2 |
| Swenson, CE | 1 |
| Tomioka, H | 1 |
| Sato, K | 1 |
| Saito, H | 1 |
| Aoyagi, T | 1 |
| Toyoda, T | 1 |
| Perumal, VK | 2 |
| Podapati, NR | 1 |
| Kesavalu, L | 1 |
| Iseman, MD | 2 |
| Yajko, DM | 1 |
| Nassos, PS | 1 |
| Hadley, WK | 1 |
| Jairam, BT | 1 |
| Rao, PN | 1 |
| Nguyen, AK | 1 |
| Farhi, DC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pharmacometrics to Advance Novel Regimens for Drug-resistant Tuberculosis[NCT03827811] | 625 participants (Anticipated) | Observational | 2020-01-30 | Recruiting | |||
| A Phase 2 Trial to Evaluate the Early Bactericidal Activity, Safety and Tolerability of the Following: TMC207 Plus PA-824 Plus Pyrazinamide Plus Clofazimine, TMC207 Plus PA-824 Plus Pyrazinamide, TMC207 Plus PA-824 Plus Clofazimine Alone, TMC207 Plus Pyra[NCT01691534] | Phase 2 | 105 participants (Actual) | Interventional | 2012-10-31 | Completed | ||
| An Open Label, Randomized Controlled Trial to Establish the Efficacy and Safety of a Study Strategy Consisting of 6 Months of Bedaquiline (BDQ), Delamanid (DLM), and Linezolid (LNZ), With Levofloxacin (LVX) and Clofazimine (CFZ) Compared to the Current So[NCT04062201] | Phase 3 | 402 participants (Actual) | Interventional | 2019-08-22 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT01691534)
Timeframe: 14 consecutive days of treatment
| Intervention | log10CFU/ml/day (Mean) |
|---|---|
| TMC207, PA-824, Pyrazinamide and Clofazimine (J-PA-Z-C) | 0.115 |
| TMC207, PA-824 and Pyrazinamide (J-PA-Z) | 0.167 |
| TMC207, PA-824 and Clofazimine (J-PA-C) | 0.076 |
| TMC207, Pyrazinamide and Clofazimine (J-Z-C) | 0.124 |
| Pyrazinamide (Z) | 0.036 |
| Clofazimine (C) | -0.017 |
| Rifafour | 0.151 |
(NCT01691534)
Timeframe: Days 0-14
| Intervention | percentage of change in time/day (Mean) |
|---|---|
| TMC207, PA-824, Pyrazinamide and Clofazimine (J-PA-Z-C) | 6.3 |
| TMC207, PA-824 and Pyrazinamide (J-PA-Z) | 7.0 |
| TMC207, PA-824 and Clofazimine (J-PA-C) | 4.3 |
| TMC207, Pyrazinamide and Clofazimine (J-Z-C) | 4.9 |
| Pyrazinamide (Z) | 2.0 |
| Clofazimine (C) | -0.3 |
| Rifafour | 6.3 |
(NCT01691534)
Timeframe: Day 0-2
| Intervention | percentage of change in time/day (Mean) |
|---|---|
| TMC207, PA-824, Pyrazinamide and Clofazimine (J-PA-Z-C) | 10.6 |
| TMC207, PA-824 and Pyrazinamide (J-PA-Z) | 13.2 |
| TMC207, PA-824 and Clofazimine (J-PA-C) | 6.0 |
| TMC207, Pyrazinamide and Clofazimine (J-Z-C) | 9.1 |
| Pyrazinamide (Z) | 4.7 |
| Clofazimine (C) | 2.1 |
| Rifafour | 12.9 |
(NCT01691534)
Timeframe: Days 7-14
| Intervention | percentage of change in time/day (Mean) |
|---|---|
| TMC207, PA-824, Pyrazinamide and Clofazimine (J-PA-Z-C) | 3.6 |
| TMC207, PA-824 and Pyrazinamide (J-PA-Z) | 4.5 |
| TMC207, PA-824 and Clofazimine (J-PA-C) | 3.1 |
| TMC207, Pyrazinamide and Clofazimine (J-Z-C) | 3.0 |
| Pyrazinamide (Z) | 0.8 |
| Clofazimine (C) | -1.3 |
| Rifafour | 4.4 |
(NCT01691534)
Timeframe: Days 0-2
| Intervention | log10CFU/ml/day (Mean) |
|---|---|
| TMC207, PA-824, Pyrazinamide and Clofazimine (J-PA-Z-C) | 0.161 |
| TMC207, PA-824 and Pyrazinamide (J-PA-Z) | 0.196 |
| TMC207, PA-824 and Clofazimine (J-PA-C) | 0.062 |
| TMC207, Pyrazinamide and Clofazimine (J-Z-C) | 0.132 |
| Pyrazinamide (Z) | 0.080 |
| Clofazimine (C) | 0.018 |
| Rifafour | 0.141 |
(NCT01691534)
Timeframe: Day 7-14
| Intervention | log10CFU/ml/day (Mean) |
|---|---|
| TMC207, PA-824, Pyrazinamide and Clofazimine (J-PA-Z-C) | 0.085 |
| TMC207, PA-824 and Pyrazinamide (J-PA-Z) | 0.146 |
| TMC207, PA-824 and Clofazimine (J-PA-C) | 0.085 |
| TMC207, Pyrazinamide and Clofazimine (J-Z-C) | 0.118 |
| Pyrazinamide (Z) | 0.022 |
| Clofazimine (C) | -0.038 |
| Rifafour | 0.157 |
8 reviews available for clofazimine and Tuberculosis
| Article | Year |
|---|---|
A medicinal chemists' guide to the unique difficulties of lead optimization for tuberculosis.
Topics: Animals; Antitubercular Agents; Drug Discovery; Humans; Lung; Mycobacterium tuberculosis; Tuberculos | 2013 |
SAR analysis of new anti-TB drugs currently in pre-clinical and clinical development.
Topics: Animals; Antitubercular Agents; Humans; Mycobacterium tuberculosis; Structure-Activity Relationship; | 2014 |
Molecule Property Analyses of Active Compounds for
Topics: Antitubercular Agents; Bacterial Proteins; Drug Discovery; Drug Resistance, Bacterial; Humans; Mycob | 2020 |
Tuberculosis Drug Discovery: Challenges and New Horizons.
Topics: Antitubercular Agents; COVID-19 Drug Treatment; Drug Discovery; Humans; Mycobacterium tuberculosis; | 2022 |
Mutations Associated with Pyrazinamide Resistance in Mycobacterium tuberculosis: A Review and Update.
Topics: Amidohydrolases; Antitubercular Agents; Clofazimine; Coenzyme A; Drug Resistance, Bacterial; Fluoroq | 2022 |
[Research progress on the anti⁃tuberculosis effect of riminophenazines].
Topics: Antitubercular Agents; Clofazimine; Humans; Tuberculosis | 2019 |
Clofazimine: current status and future prospects.
Topics: Anti-Inflammatory Agents; Antitubercular Agents; Clofazimine; Drug Resistance, Multiple, Bacterial; | 2012 |
Clofazimine.
Topics: Animals; Antitubercular Agents; Clofazimine; Humans; Treatment Outcome; Tuberculosis | 2008 |
3 trials available for clofazimine and Tuberculosis
| Article | Year |
|---|---|
Efficacy and safety of an innovative short-course regimen containing clofazimine for treatment of drug-susceptible tuberculosis: a clinical trial.
Topics: Antitubercular Agents; Clofazimine; Drug Therapy, Combination; Humans; Isoniazid; Prothionamide; Pyr | 2023 |
Effect of Clofazimine Concentration on QT Prolongation in Patients Treated for Tuberculosis.
Topics: Adult; Clofazimine; Electrocardiography; Heart Rate; Humans; Long QT Syndrome; South Africa; Tubercu | 2021 |
Bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquiline.
Topics: Adult; Antitubercular Agents; Clofazimine; Diarylquinolines; Drug Therapy, Combination; Female; HIV | 2015 |
Bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquiline.
Topics: Adult; Antitubercular Agents; Clofazimine; Diarylquinolines; Drug Therapy, Combination; Female; HIV | 2015 |
Bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquiline.
Topics: Adult; Antitubercular Agents; Clofazimine; Diarylquinolines; Drug Therapy, Combination; Female; HIV | 2015 |
Bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquiline.
Topics: Adult; Antitubercular Agents; Clofazimine; Diarylquinolines; Drug Therapy, Combination; Female; HIV | 2015 |
57 other studies available for clofazimine and Tuberculosis
| Article | Year |
|---|---|
Antitubercular activity of quinolizidinyl/pyrrolizidinylalkyliminophenazines.
Topics: Animals; Antitubercular Agents; Cell Line; Cell Survival; Chlorocebus aethiops; Humans; Microbial Se | 2014 |
The Effect of Tuberculosis Antimicrobials on the Immunometabolic Profiles of Primary Human Macrophages Stimulated with
Topics: Antitubercular Agents; Clofazimine; Cytokines; Glycolysis; Humans; Lipopolysaccharides; Macrophages; | 2021 |
Assessment of the efficacy of clofazimine alone and in combination with primary agents against Mycobacterium tuberculosis in vitro.
Topics: Animals; Antitubercular Agents; Clofazimine; Ethambutol; Humans; Isoniazid; Mice; Mycobacterium tube | 2022 |
Do Anti-tuberculosis Drugs Reach Their Target?─High-Resolution Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry Imaging Provides Information on Drug Penetration into Necrotic Granulomas.
Topics: Animals; Antitubercular Agents; Clofazimine; Granuloma; Humans; Lasers; Mice; Mycobacterium tubercul | 2022 |
Superior Efficacy of a TBI-166, Bedaquiline, and Pyrazinamide Combination Regimen in a Murine Model of Tuberculosis.
Topics: Animals; Antitubercular Agents; Clofazimine; Diarylquinolines; Disease Models, Animal; Isoniazid; Li | 2022 |
Respirable Clofazimine Particles Produced by Air Jet Milling Technique Are Efficacious in Treatment of BALB/c Mice with Chronic Mycobacterium tuberculosis Infection.
Topics: Animals; Antitubercular Agents; Clofazimine; Mice; Mice, Inbred BALB C; Mycobacterium tuberculosis; | 2022 |
New Drugs and Regimens for Tuberculosis Disease Treatment in Children and Adolescents.
Topics: Adolescent; Antitubercular Agents; Clofazimine; Humans; Linezolid; Tuberculosis; Tuberculosis, Multi | 2022 |
Extemporaneously compounded liquid formulations of clofazimine.
Topics: Child; Clofazimine; Drug Compounding; Humans; Leprosy; Pharmaceutical Services; Tuberculosis | 2023 |
Bedaquiline resistance pattern in clofazimine-resistant clinical isolates of tuberculosis patients.
Topics: Antitubercular Agents; Clofazimine; Diarylquinolines; Humans; Tuberculosis | 2023 |
Development of low-cost, weight-adjustable clofazimine mini-tablets for treatment of tuberculosis in pediatrics.
Topics: Animals; Child; Clofazimine; Humans; Rats; Rats, Sprague-Dawley; Tablets; Tuberculosis; Tuberculosis | 2023 |
Clofazimine nanoclusters show high efficacy in experimental TB with amelioration in paradoxical lung inflammation.
Topics: Animals; Clofazimine; Inflammation; Mice; Pneumonia; Respiratory Aerosols and Droplets; Tuberculosis | 2023 |
Topics: Animals; Antitubercular Agents; Clofazimine; Disease Models, Animal; Mice; Microbial Sensitivity Tes | 2019 |
Polymeric nanobiotics as a novel treatment for mycobacterial infections.
Topics: Animals; Antitubercular Agents; Clofazimine; Delayed-Action Preparations; Disease Models, Animal; Dr | 2019 |
Clofazimine enhances the efficacy of BCG revaccination via stem cell-like memory T cells.
Topics: Animals; BCG Vaccine; Clofazimine; Drug Therapy, Combination; Female; Immunization, Secondary; Immun | 2020 |
Isolated multidrug-resistant tubercular tenosynovitis of the flexor tendon of the little finger.
Topics: Adult; Anti-Bacterial Agents; Anti-Inflammatory Agents; Antitubercular Agents; Clofazimine; Cycloser | 2021 |
Clofazimine functionalized polymeric nanoparticles for brain delivery in the tuberculosis treatment.
Topics: Brain; Clofazimine; Drug Carriers; Drug Delivery Systems; Humans; Nanoparticles; Tissue Distribution | 2021 |
Sterilizing Effects of Novel Regimens Containing TB47, Clofazimine, and Linezolid in a Murine Model of Tuberculosis.
Topics: Animals; Antitubercular Agents; Clofazimine; Disease Models, Animal; Linezolid; Mice; Mice, Inbred B | 2021 |
Intragenic Distribution of IS
Topics: Antitubercular Agents; Clofazimine; Computational Biology; DNA Transposable Elements; Drug Resistanc | 2021 |
Clofazimine encapsulation in nanoporous silica particles for the oral treatment of antibiotic-resistant Mycobacterium tuberculosis infections.
Topics: Administration, Oral; Caco-2 Cells; Clofazimine; Drug Resistance, Bacterial; Humans; Mycobacterium t | 2017 |
Varying effects of common tuberculosis drugs on enhancing clofazimine activity in vitro.
Topics: Antitubercular Agents; Clofazimine; Drug Evaluation, Preclinical; Drug Synergism; Humans; Mycobacter | 2017 |
Clofazimine protects against Mycobacterium tuberculosis dissemination in the central nervous system following aerosol challenge in a murine model.
Topics: Animals; Antitubercular Agents; Blood-Brain Barrier; Brain; Clofazimine; Disease Models, Animal; Fem | 2018 |
Verapamil Increases the Bioavailability and Efficacy of Bedaquiline but Not Clofazimine in a Murine Model of Tuberculosis.
Topics: Animals; Antitubercular Agents; Biological Availability; Calcium Channel Blockers; Clofazimine; Colo | 2018 |
Excipient-Free Pulmonary Delivery and Macrophage Targeting of Clofazimine via Air Jet Micronization.
Topics: Antitubercular Agents; Clofazimine; Excipients; Humans; Macrophages; Macrophages, Alveolar; Microbia | 2017 |
Impact of Clofazimine Dosing on Treatment Shortening of the First-Line Regimen in a Mouse Model of Tuberculosis.
Topics: Animals; Antitubercular Agents; Clofazimine; Disease Models, Animal; Female; Mice; Mice, Inbred BALB | 2018 |
Clofazimine drug susceptibility testing for Mycobacterium tuberculosis: the case of using the right diluent.
Topics: Clofazimine; Data Accuracy; Humans; Laboratories; Microbial Sensitivity Tests; Mycobacterium tubercu | 2018 |
Validating a 14-Drug Microtiter Plate Containing Bedaquiline and Delamanid for Large-Scale Research Susceptibility Testing of Mycobacterium tuberculosis.
Topics: Antitubercular Agents; Clofazimine; Diarylquinolines; Drug Resistance, Multiple, Bacterial; Humans; | 2018 |
Ultra-rapid near universal TB drug regimen identified via parabolic response surface platform cures mice of both conventional and high susceptibility.
Topics: Adamantane; Animals; Antitubercular Agents; Clofazimine; Diarylquinolines; Disease Models, Animal; D | 2018 |
Treatment-Shortening Effect of a Novel Regimen Combining Clofazimine and High-Dose Rifapentine in Pathologically Distinct Mouse Models of Tuberculosis.
Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Clofazimine; Disease Models, Animal; Dr | 2019 |
Acquisition of Cross-Resistance to Bedaquiline and Clofazimine following Treatment for Tuberculosis in Pakistan.
Topics: Antitubercular Agents; Clofazimine; Diarylquinolines; Drug Resistance, Microbial; Drug Resistance, M | 2019 |
Synthesis and biological evaluation of novel 2-methoxypyridylamino-substituted riminophenazine derivatives as antituberculosis agents.
Topics: Administration, Oral; Aminopyridines; Animals; Antitubercular Agents; Clofazimine; Drug Design; Half | 2014 |
Limited activity of clofazimine as a single drug in a mouse model of tuberculosis exhibiting caseous necrotic granulomas.
Topics: Animals; Antitubercular Agents; Bacterial Load; Clofazimine; Disease Models, Animal; Female; Granulo | 2014 |
Acquired resistance of Mycobacterium tuberculosis to bedaquiline.
Topics: Animals; Antitubercular Agents; Bacterial Proteins; Base Sequence; Clofazimine; Diarylquinolines; Dr | 2014 |
Contribution of the nitroimidazoles PA-824 and TBA-354 to the activity of novel regimens in murine models of tuberculosis.
Topics: Animals; Antitubercular Agents; Clofazimine; Diarylquinolines; Disease Models, Animal; Drug Therapy, | 2015 |
Clofazimine shortens the duration of the first-line treatment regimen for experimental chemotherapy of tuberculosis.
Topics: Animals; Antitubercular Agents; Clofazimine; Disease Models, Animal; Female; Mice; Mice, Inbred BALB | 2015 |
Pharmacokinetics and pharmacodynamics of clofazimine in a mouse model of tuberculosis.
Topics: Animals; Antitubercular Agents; Chromatography, Liquid; Clofazimine; Female; Mass Spectrometry; Mice | 2015 |
A reader's guide to the bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquiline.
Topics: Clofazimine; Diarylquinolines; Female; HIV Infections; Humans; Male; Nitroimidazoles; Pyrazinamide; | 2015 |
In vitro activity against Mycobacterium tuberculosis of levofloxacin, moxifloxacin and UB-8902 in combination with clofazimine and pretomanid.
Topics: Antitubercular Agents; Clofazimine; Drug Interactions; Fluoroquinolones; Humans; Microbial Sensitivi | 2015 |
Clofazimine Contributes Sustained Antimicrobial Activity after Treatment Cessation in a Mouse Model of Tuberculosis Chemotherapy.
Topics: Animals; Antitubercular Agents; Clofazimine; Disease Models, Animal; Drug Combinations; Drug Therapy | 2016 |
[Activities of clofazimine against Mycobacterium tuberculosis in vitro and in vivo].
Topics: Animals; Clofazimine; Female; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Mycobacterium | 2008 |
Clofazimine analogs with efficacy against experimental tuberculosis and reduced potential for accumulation.
Topics: Administration, Oral; Animals; Antitubercular Agents; Cell Line; Chlorocebus aethiops; Clofazimine; | 2011 |
Eradication of bacterial persisters with antibiotic-generated hydroxyl radicals.
Topics: Anti-Bacterial Agents; Clofazimine; Drug Resistance, Bacterial; Green Fluorescent Proteins; In Vitro | 2012 |
Inhaled microparticles containing clofazimine are efficacious in treatment of experimental tuberculosis in mice.
Topics: Administration, Inhalation; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antitubercular Agents; | 2013 |
[Antituberculous activity of compound B-663].
Topics: Clofazimine; Humans; Mycobacterium tuberculosis; Tuberculosis | 1958 |
Chemotherapy of leprosy.
Topics: Anti-Bacterial Agents; Clofazimine; Dapsone; Dose-Response Relationship, Drug; Drug Combinations; Dr | 2004 |
Long-term cure of disseminated Mycobacterium avium infection in a cat.
Topics: Administration, Oral; Animals; Anti-Bacterial Agents; Cat Diseases; Cats; Clarithromycin; Clofazimin | 2007 |
Carryover of clofazimine into culture media.
Topics: Animals; Clofazimine; Colony Count, Microbial; Culture Media; Liver; Lung; Mice; Mice, Mutant Strain | 1995 |
Treatment of localized Mycobacterium avium complex infection with clofazimine and doxycycline in a cat.
Topics: Animals; Anti-Bacterial Agents; Cat Diseases; Cats; Clofazimine; Doxycycline; Granuloma; Leprostatic | 1995 |
Chemotherapeutic activity of clofazimine and its analogues against Mycobacterium tuberculosis. In vitro, intracellular, and in vivo studies.
Topics: Animals; Clofazimine; Liver; Lung; Mice; Mice, Inbred C57BL; Microbial Sensitivity Tests; Mycobacter | 1995 |
Antituberculosis activities of clofazimine and its new analogs B4154 and B4157.
Topics: Animals; Antitubercular Agents; Cell Line; Clofazimine; Drug Resistance, Multiple; Female; Isoniazid | 1996 |
Effective treatment of acute and chronic murine tuberculosis with liposome-encapsulated clofazimine.
Topics: Acute Disease; Animals; Chronic Disease; Clofazimine; Drug Carriers; Leprostatic Agents; Liposomes; | 1999 |
Activity of clarithromycin against Mycobacterium avium complex infection in beige mice.
Topics: Amikacin; Animals; Anti-Infective Agents; Antitubercular Agents; Clarithromycin; Clofazimine; Diseas | 1992 |
TLC G-65 in combination with other agents in the therapy of Mycobacterium avium infection in beige mice.
Topics: Amikacin; Animals; Antitubercular Agents; Clarithromycin; Clofazimine; Culture Media; Drug Therapy, | 1992 |
[Therapeutic efficacy of kanamycin and clofazimine combined with muramyl dipeptide against Mycobacterium intracellulare infection induced in mice].
Topics: Acetylmuramyl-Alanyl-Isoglutamine; Animals; Clofazimine; Drug Evaluation; Drug Therapy, Combination; | 1991 |
[Drugs used in tuberculosis and leprosy].
Topics: Administration, Oral; Antibiotics, Antitubercular; Clofazimine; Dapsone; Humans; Injections, Intramu | 1990 |
In vivo activity of amikacin alone or in combination with clofazimine or rifabutin or both against acute experimental Mycobacterium avium complex infections in beige mice.
Topics: Amikacin; Animals; Antitubercular Agents; Clofazimine; Drug Therapy, Combination; Male; Mice; Mice, | 1988 |
Therapeutic implications of inhibition versus killing of Mycobacterium avium complex by antimicrobial agents.
Topics: Acquired Immunodeficiency Syndrome; Ciprofloxacin; Clofazimine; Humans; Mycobacterium avium; Rifabut | 1987 |
Activity of rifabutin alone or in combination with clofazimine or ethambutol or both against acute and chronic experimental Mycobacterium intracellulare infections.
Topics: Animals; Chronic Disease; Clofazimine; Drug Therapy, Combination; Ethambutol; Male; Mice; Mice, Inbr | 1987 |